As it nears the clinic with potential Alzheimer’s disease drugs, Prothena Corporation plc will lean on the many years of experience its leadership team has in the space, including their time at Elan Corporation working on one of the first late-stage antibodies targeting amyloid-beta. The company is working on three preclinical Alzheimer’s programs now and it sees Biogen, Inc.’s aducanumab as helping to lay the groundwork for next-generation amyloid-targeting therapies, like the one in Prothena’s pipeline.
Prothena Sees Potential In Targeting Amyloid, Validated By Biogen
CEO Gene Kinney Describes Company’s Emerging Alzheimer’s Programs
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.
